Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EPIX ESSA Pharma	$0.21 -5.2%	$0.90	$0.18 ▼ $6.48	$9.75M	1.57	3.02 million shs	2.72 million shs
LIMN Liminatus Pharma	$1.73 -11.7%	$3.21	$1.12 ▼ $33.66	$45.01M	N/A	1.26 million shs	1.15 million shs
MRSN Mersana Therapeutics	$8.28 +3.5%	$7.22	$5.21 ▼ $70.75	$41.32M	0.9	45,827 shs	75,589 shs
PLUR Pluri	$4.62 -1.8%	$4.90	$3.33 ▼ $7.13	$37.61M	0.66	5,404 shs	10,302 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EPIX ESSA Pharma	0.00%	+2.54%	-11.01%	-88.12%	-96.60%
LIMN Liminatus Pharma	0.00%	+19.31%	-38.87%	-80.82%	+172,999,900.00%
MRSN Mersana Therapeutics	0.00%	+9.38%	+16.29%	+14.21%	-83.76%
PLUR Pluri	0.00%	+5.37%	-4.85%	-19.74%	-11.25%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EPIX ESSA Pharma	$0.21 -5.2%	$0.90	$0.18 ▼ $6.48	$9.75M	1.57	3.02 million shs	2.72 million shs
LIMN Liminatus Pharma	$1.73 -11.7%	$3.21	$1.12 ▼ $33.66	$45.01M	N/A	1.26 million shs	1.15 million shs
MRSN Mersana Therapeutics	$8.28 +3.5%	$7.22	$5.21 ▼ $70.75	$41.32M	0.9	45,827 shs	75,589 shs
PLUR Pluri	$4.62 -1.8%	$4.90	$3.33 ▼ $7.13	$37.61M	0.66	5,404 shs	10,302 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EPIX ESSA Pharma	0.00%	+2.54%	-11.01%	-88.12%	-96.60%
LIMN Liminatus Pharma	0.00%	+19.31%	-38.87%	-80.82%	+172,999,900.00%
MRSN Mersana Therapeutics	0.00%	+9.38%	+16.29%	+14.21%	-83.76%
PLUR Pluri	0.00%	+5.37%	-4.85%	-19.74%	-11.25%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EPIX ESSA Pharma	1.75	Reduce	$2.00	870.40% Upside
LIMN Liminatus Pharma	1.00	Sell	N/A	N/A
MRSN Mersana Therapeutics	2.71	Moderate Buy	$56.60	583.57% Upside
PLUR Pluri	2.00	Hold	$12.00	160.02% Upside

Current Analyst Ratings Breakdown

Latest EPIX, PLUR, MRSN, and LIMN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/27/2025	EPIX ESSA Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/27/2025	LIMN Liminatus Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/27/2025	MRSN Mersana Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/27/2025	PLUR Pluri	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/14/2025	MRSN Mersana Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$250.00 ➝ $36.00
8/14/2025	MRSN Mersana Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$125.00 ➝ $30.00
8/13/2025	MRSN Mersana Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$17.00

(Data available from 10/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EPIX ESSA Pharma	N/A	N/A	N/A	N/A	$2.81 per share	N/A
LIMN Liminatus Pharma	N/A	N/A	N/A	N/A	N/A	N/A
MRSN Mersana Therapeutics	$40.50M	1.02	N/A	N/A	($1.92) per share	-4.31
PLUR Pluri	$1.34M	28.10	N/A	N/A	($0.11) per share	-41.95

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EPIX ESSA Pharma	-$28.54M	-$0.56	N/A	N/A	N/A	N/A	-21.71%	-21.22%	12/16/2025 (Estimated)
LIMN Liminatus Pharma	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
MRSN Mersana Therapeutics	-$69.19M	-$14.62	N/A	N/A	N/A	-212.94%	N/A	-54.85%	11/12/2025 (Estimated)
PLUR Pluri	-$22.58M	-$5.17	N/A	∞	N/A	-1,701.19%	-4,191.91%	-88.27%	N/A

Latest EPIX, PLUR, MRSN, and LIMN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/17/2025	Q4 2025	PLUR Pluri	-$0.73	-$2.62	-$1.89	-$2.62	$0.40 million	$0.91 million
8/13/2025	Q3 2025	EPIX ESSA Pharma	-$0.17	-$0.09	+$0.08	-$0.09	N/A	N/A
8/13/2025	Q2 2025	MRSN Mersana Therapeutics	-$3.75	-$4.08	-$0.33	-$4.87	$6.06 million	$3.06 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EPIX ESSA Pharma	$1.69	819.99%	N/A	N/A	N/A
LIMN Liminatus Pharma	N/A	N/A	N/A	N/A	N/A
MRSN Mersana Therapeutics	N/A	N/A	N/A	N/A	N/A
PLUR Pluri	N/A	N/A	N/A	N/A	N/A

Latest EPIX, PLUR, MRSN, and LIMN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
1/1/2100	EPIX ESSA Pharma	--	$1.69		8/25/2025	8/19/2025	8/22/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EPIX ESSA Pharma	N/A	69.06	69.06
LIMN Liminatus Pharma	N/A	N/A	N/A
MRSN Mersana Therapeutics	N/A	1.35	1.35
PLUR Pluri	51.65	0.68	0.68

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EPIX ESSA Pharma	75.12%
LIMN Liminatus Pharma	N/A
MRSN Mersana Therapeutics	93.92%
PLUR Pluri	16.59%

Insider Ownership

Company	Insider Ownership
EPIX ESSA Pharma	15.50%
LIMN Liminatus Pharma	N/A
MRSN Mersana Therapeutics	13.00%
PLUR Pluri	25.93%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EPIX ESSA Pharma	50	47.31 million	39.98 million	Optionable
LIMN Liminatus Pharma	N/A	26.01 million	N/A	N/A
MRSN Mersana Therapeutics	150	4.99 million	4.34 million	Optionable
PLUR Pluri	150	8.16 million	6.04 million	Optionable

EPIX, PLUR, MRSN, and LIMN Headlines

Recent News About These Companies

Pluri files to sell 3.425M common shares for holders

September 17, 2025 | msn.com

Pluri Resolves Nasdaq Compliance Issue with New Director

September 12, 2025 | tipranks.com

Pluri Appoints Eitan Ajchenbaum to Board of Directors

September 11, 2025 | tipranks.com

Pluri Inc. director not re-elected, Nasdaq compliance cure period granted

July 5, 2025 | investing.com

Insider Buying: Pluri Inc. (NASDAQ:PLUR) Director Purchases 976,139 Shares of Stock

July 2, 2025 | insidertrades.com

Alliance Global Partners Initiates Coverage of Pluri (PLUR) with Buy Recommendation

June 2, 2025 | msn.com

Pluri Inc. reschedules 2025 annual meeting

May 27, 2025 | investing.com

BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials

May 27, 2025 | prnewswire.com

Brainstorm Cell Therapeutics outlines imminent Phase 3b ALS trial launch following FDA clearance and expanded manufacturing plans

May 19, 2025 | msn.com

Pluri Inc.: Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd.

May 16, 2025 | finanznachrichten.de

Pluri CEO Issues Shareholder Letter Highlighting Strategic Growth, Innovation, and Global Market Expansion

May 16, 2025 | tmcnet.com

Pluri: Fiscal Q3 Earnings Snapshot

May 13, 2025 | timesunion.comT

Pluri Inc. acquires majority stake in Kokomodo Ltd.

April 30, 2025 | uk.investing.com

Pluri acquires 71% stake in Kokomodo

April 29, 2025 | foodbusinessnews.netF

Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd.

April 28, 2025 | globenewswire.com

Pluri Inc. enters agreement, issues pre-funded warrants

April 27, 2025 | investing.com

Ukraine gains access to Israeli anti-radiation drug amid nuclear threats

April 21, 2025 | msn.com

Ukraine prepares for nuclear emergency - Israel to help save thousands

April 21, 2025 | msn.com

In case of a nuclear event, Ukraine to use Israeli placenta-based emergency treatment

April 20, 2025 | msn.com

Innovative Treatment Aims to Protect Ukrainians from Nuclear Radiation Threat

April 17, 2025 | themunicheye.comT

New MarketBeat Followers Over Time

Media Sentiment Over Time

EPIX, PLUR, MRSN, and LIMN Company Descriptions

ESSA Pharma NASDAQ:EPIX

$0.21 -0.01 (-5.20%)

Closing price 10/3/2025 04:00 PM Eastern

Extended Trading

$0.20 0.00 (-1.02%)

As of 10/3/2025 07:59 PM Eastern

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Liminatus Pharma NASDAQ:LIMN

$1.73 -0.23 (-11.73%)

As of 10/3/2025 04:00 PM Eastern

Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.

Mersana Therapeutics NASDAQ:MRSN

$8.28 +0.28 (+3.50%)

Closing price 10/3/2025 04:00 PM Eastern

Extended Trading

$8.22 -0.06 (-0.72%)

As of 10/3/2025 06:33 PM Eastern

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Pluri NASDAQ:PLUR

$4.62 -0.09 (-1.81%)

Closing price 10/3/2025 03:56 PM Eastern

Extended Trading

$4.62 0.00 (0.00%)

As of 10/3/2025 04:10 PM Eastern

Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EPIX, PLUR, MRSN, and LIMN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EPIX, PLUR, MRSN, and LIMN Earnings

Compare Dividends

Latest EPIX, PLUR, MRSN, and LIMN Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EPIX, PLUR, MRSN, and LIMN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EPIX, PLUR, MRSN, and LIMN Company Descriptions

ESSA Pharma NASDAQ:EPIX

Liminatus Pharma NASDAQ:LIMN

Mersana Therapeutics NASDAQ:MRSN

Pluri NASDAQ:PLUR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EPIX, PLUR, MRSN, and LIMN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EPIX, PLUR, MRSN, and LIMN Earnings

Compare Dividends

Latest EPIX, PLUR, MRSN, and LIMN Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EPIX, PLUR, MRSN, and LIMN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EPIX, PLUR, MRSN, and LIMN Company Descriptions

ESSA Pharma NASDAQ:EPIX

Liminatus Pharma NASDAQ:LIMN

Mersana Therapeutics NASDAQ:MRSN

Pluri NASDAQ:PLUR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools